' 
![]()
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8.2
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 Packet (10 g)
Amount Per Serving
%DV
Calories
35
Protein
9 g
0%*
Sodium
55 mg
2%
Collagen peptides (from bovine)
10 g
**
Top Medical Research Studies
9
METTL14 modifications impact AML
Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML.
Direct link between protein and cancer
We explored how specific changes to the METTL14 protein affect cancer, particularly in acute myeloid leukemia (AML). By examining the RG-rich region of METTL14, we discovered that a special form of arginine methylation called symmetric dimethylation, specifically at positions R425 and R445, plays a vital role in enhancing its function.
Our research revealed that this modification not only improves the activity of the METTL3:METTL14 complex but also influences which genes get expressed in cancer cells. We found that the presence of symmetric dimethylarginines helps the complex deposit a crucial chemical mark, known as m6A, on RNA, which is essential for the regulation of gene activity.
Furthermore, we conducted a series of experiments that indicated a potential therapeutic angle in targeting the METTL3 and PRMT5 proteins. When both are inhibited, we observed a significant drop in the expression of genes important for AML cell growth, hinting at new possibilities for treating this challenging cancer. Overall, this study highlights the intricate relationship between protein modifications and cancer biology, emphasizing the potential for more targeted approaches in therapy.
Our research revealed that this modification not only improves the activity of the METTL3:METTL14 complex but also influences which genes get expressed in cancer cells. We found that the presence of symmetric dimethylarginines helps the complex deposit a crucial chemical mark, known as m6A, on RNA, which is essential for the regulation of gene activity.
Furthermore, we conducted a series of experiments that indicated a potential therapeutic angle in targeting the METTL3 and PRMT5 proteins. When both are inhibited, we observed a significant drop in the expression of genes important for AML cell growth, hinting at new possibilities for treating this challenging cancer. Overall, this study highlights the intricate relationship between protein modifications and cancer biology, emphasizing the potential for more targeted approaches in therapy.
Read More
9
IL-19 targets glioblastoma immunosuppression
IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment.
Highly relevant cancer treatment target
Our research delved into the role of interleukin-19 (IL-19) in glioblastoma, a particularly aggressive brain cancer known for its ability to evade treatments. By analyzing RNA sequencing data from patient samples, we found that IL-19 is linked to poor survival rates and is involved in creating an immunosuppressive environment that helps the tumor thrive.
We observed that blocking IL-19 led to significant reductions in tumor progression in both treatment-sensitive and resistant glioblastoma models. This blockade also sparked changes in the immune landscape of the tumors, particularly increasing the presence of immune cells like dendritic cells that help fight cancer. Notably, IL-19 suppression reprogrammed tumor-associated macrophages, making them less supportive of tumor growth and enhancing T cell activation.
Additionally, we uncovered a new signaling pathway involving IL-19 that helps glioblastoma cells migrate and invade other tissues. To bring these findings closer to real-world applications, we developed a new type of nanoparticles designed to specifically target IL-19 in glioblastoma tissues, illustrating their potential both as a therapeutic tool and a diagnostic marker through advanced imaging techniques.
Overall, our findings present IL-19 as a promising target for enhancing cancer treatment by reversing immune suppression and limiting the invasive potential of glioblastoma cells.
We observed that blocking IL-19 led to significant reductions in tumor progression in both treatment-sensitive and resistant glioblastoma models. This blockade also sparked changes in the immune landscape of the tumors, particularly increasing the presence of immune cells like dendritic cells that help fight cancer. Notably, IL-19 suppression reprogrammed tumor-associated macrophages, making them less supportive of tumor growth and enhancing T cell activation.
Additionally, we uncovered a new signaling pathway involving IL-19 that helps glioblastoma cells migrate and invade other tissues. To bring these findings closer to real-world applications, we developed a new type of nanoparticles designed to specifically target IL-19 in glioblastoma tissues, illustrating their potential both as a therapeutic tool and a diagnostic marker through advanced imaging techniques.
Overall, our findings present IL-19 as a promising target for enhancing cancer treatment by reversing immune suppression and limiting the invasive potential of glioblastoma cells.
Read More
9
Promising lipase impact on cancer
Production and characterization of a promising microbial-derived lipase enzyme targeting BCL-2 gene expression in hepatocellular carcinoma.
Significant therapeutic relevance confirmed
We set out to explore the potential of a lipase enzyme derived from the bacterial strain Pseudomonas aeruginosa in treating liver cancer. The goal was to see how this microbial protein might impact cancer cells, specifically by targeting the BCL-2 gene, which plays a significant role in cancer cell survival.
To achieve this, we isolated several strains of P. aeruginosa from various biological samples and identified one with the highest lipase activity. After enhancing the enzyme's production through random mutagenesis, we used submerged fermentation techniques to optimize the growth conditions. Under these optimized parameters, we achieved a notable increase in lipase activity, which we then purified for testing.
Our results were encouraging. The purified lipase proved stable and effective, exhibiting significant anticancer activity in cultured liver cancer cells, known as HepG-2. Notably, we found that treatment with the enzyme led to a substantial reduction in Bcl-2 gene expression, promoting cancer cell death through apoptosis. Importantly, the lipase showed no harmful effects on normal cells, suggesting its potential as a safe therapeutic option for liver cancer.
Overall, our findings suggest that lipase from P. aeruginosa could be a promising new approach to tackle hepatocellular carcinoma, addressing some of the shortcomings in existing cancer treatments.
To achieve this, we isolated several strains of P. aeruginosa from various biological samples and identified one with the highest lipase activity. After enhancing the enzyme's production through random mutagenesis, we used submerged fermentation techniques to optimize the growth conditions. Under these optimized parameters, we achieved a notable increase in lipase activity, which we then purified for testing.
Our results were encouraging. The purified lipase proved stable and effective, exhibiting significant anticancer activity in cultured liver cancer cells, known as HepG-2. Notably, we found that treatment with the enzyme led to a substantial reduction in Bcl-2 gene expression, promoting cancer cell death through apoptosis. Importantly, the lipase showed no harmful effects on normal cells, suggesting its potential as a safe therapeutic option for liver cancer.
Overall, our findings suggest that lipase from P. aeruginosa could be a promising new approach to tackle hepatocellular carcinoma, addressing some of the shortcomings in existing cancer treatments.
Read More
Most Useful Reviews
8.8
Joint support
I felt the difference! Initially sceptical, I have cancer and arthritis. After just two months on this supplement, I noticed a remarkable change. It is completely flavourless, so I mix it into my coffee every morning and have started gifting it to family and friends suffering from joint pain or brittle nails/hair. Highly recommend!
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 9 Researches
8.2
9
METTL14 modifications impact AML
Specific sDMA modifications on the RGG/RG motif of METTL14 regulate its function in AML.
Direct link between protein and cancer
We explored how specific changes to the METTL14 protein affect cancer, particularly in acute myeloid leukemia (AML). By examining the RG-rich region of METTL14, we discovered that a special form of arginine methylation called symmetric dimethylation, specifically at positions R425 and R445, plays a vital role in enhancing its function.
Our research revealed that this modification not only improves the activity of the METTL3:METTL14 complex but also influences which genes get expressed in cancer cells. We found that the presence of symmetric dimethylarginines helps the complex deposit a crucial chemical mark, known as m6A, on RNA, which is essential for the regulation of gene activity.
Furthermore, we conducted a series of experiments that indicated a potential therapeutic angle in targeting the METTL3 and PRMT5 proteins. When both are inhibited, we observed a significant drop in the expression of genes important for AML cell growth, hinting at new possibilities for treating this challenging cancer. Overall, this study highlights the intricate relationship between protein modifications and cancer biology, emphasizing the potential for more targeted approaches in therapy.
Our research revealed that this modification not only improves the activity of the METTL3:METTL14 complex but also influences which genes get expressed in cancer cells. We found that the presence of symmetric dimethylarginines helps the complex deposit a crucial chemical mark, known as m6A, on RNA, which is essential for the regulation of gene activity.
Furthermore, we conducted a series of experiments that indicated a potential therapeutic angle in targeting the METTL3 and PRMT5 proteins. When both are inhibited, we observed a significant drop in the expression of genes important for AML cell growth, hinting at new possibilities for treating this challenging cancer. Overall, this study highlights the intricate relationship between protein modifications and cancer biology, emphasizing the potential for more targeted approaches in therapy.
Read More
9
IL-19 targets glioblastoma immunosuppression
IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment.
Highly relevant cancer treatment target
Our research delved into the role of interleukin-19 (IL-19) in glioblastoma, a particularly aggressive brain cancer known for its ability to evade treatments. By analyzing RNA sequencing data from patient samples, we found that IL-19 is linked to poor survival rates and is involved in creating an immunosuppressive environment that helps the tumor thrive.
We observed that blocking IL-19 led to significant reductions in tumor progression in both treatment-sensitive and resistant glioblastoma models. This blockade also sparked changes in the immune landscape of the tumors, particularly increasing the presence of immune cells like dendritic cells that help fight cancer. Notably, IL-19 suppression reprogrammed tumor-associated macrophages, making them less supportive of tumor growth and enhancing T cell activation.
Additionally, we uncovered a new signaling pathway involving IL-19 that helps glioblastoma cells migrate and invade other tissues. To bring these findings closer to real-world applications, we developed a new type of nanoparticles designed to specifically target IL-19 in glioblastoma tissues, illustrating their potential both as a therapeutic tool and a diagnostic marker through advanced imaging techniques.
Overall, our findings present IL-19 as a promising target for enhancing cancer treatment by reversing immune suppression and limiting the invasive potential of glioblastoma cells.
We observed that blocking IL-19 led to significant reductions in tumor progression in both treatment-sensitive and resistant glioblastoma models. This blockade also sparked changes in the immune landscape of the tumors, particularly increasing the presence of immune cells like dendritic cells that help fight cancer. Notably, IL-19 suppression reprogrammed tumor-associated macrophages, making them less supportive of tumor growth and enhancing T cell activation.
Additionally, we uncovered a new signaling pathway involving IL-19 that helps glioblastoma cells migrate and invade other tissues. To bring these findings closer to real-world applications, we developed a new type of nanoparticles designed to specifically target IL-19 in glioblastoma tissues, illustrating their potential both as a therapeutic tool and a diagnostic marker through advanced imaging techniques.
Overall, our findings present IL-19 as a promising target for enhancing cancer treatment by reversing immune suppression and limiting the invasive potential of glioblastoma cells.
Read More
9
Promising lipase impact on cancer
Production and characterization of a promising microbial-derived lipase enzyme targeting BCL-2 gene expression in hepatocellular carcinoma.
Significant therapeutic relevance confirmed
We set out to explore the potential of a lipase enzyme derived from the bacterial strain Pseudomonas aeruginosa in treating liver cancer. The goal was to see how this microbial protein might impact cancer cells, specifically by targeting the BCL-2 gene, which plays a significant role in cancer cell survival.
To achieve this, we isolated several strains of P. aeruginosa from various biological samples and identified one with the highest lipase activity. After enhancing the enzyme's production through random mutagenesis, we used submerged fermentation techniques to optimize the growth conditions. Under these optimized parameters, we achieved a notable increase in lipase activity, which we then purified for testing.
Our results were encouraging. The purified lipase proved stable and effective, exhibiting significant anticancer activity in cultured liver cancer cells, known as HepG-2. Notably, we found that treatment with the enzyme led to a substantial reduction in Bcl-2 gene expression, promoting cancer cell death through apoptosis. Importantly, the lipase showed no harmful effects on normal cells, suggesting its potential as a safe therapeutic option for liver cancer.
Overall, our findings suggest that lipase from P. aeruginosa could be a promising new approach to tackle hepatocellular carcinoma, addressing some of the shortcomings in existing cancer treatments.
To achieve this, we isolated several strains of P. aeruginosa from various biological samples and identified one with the highest lipase activity. After enhancing the enzyme's production through random mutagenesis, we used submerged fermentation techniques to optimize the growth conditions. Under these optimized parameters, we achieved a notable increase in lipase activity, which we then purified for testing.
Our results were encouraging. The purified lipase proved stable and effective, exhibiting significant anticancer activity in cultured liver cancer cells, known as HepG-2. Notably, we found that treatment with the enzyme led to a substantial reduction in Bcl-2 gene expression, promoting cancer cell death through apoptosis. Importantly, the lipase showed no harmful effects on normal cells, suggesting its potential as a safe therapeutic option for liver cancer.
Overall, our findings suggest that lipase from P. aeruginosa could be a promising new approach to tackle hepatocellular carcinoma, addressing some of the shortcomings in existing cancer treatments.
Read More
9
Ivonescimab shows improved survival
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Study highlights protein treatment relevance.
We conducted a phase 3 clinical trial called HARMONi-2, comparing the effectiveness of a new drug, ivonescimab, with the established treatment, pembrolizumab, for patients with advanced non-small cell lung cancer that tests positive for PD-L1. This study focused on individuals who had not received prior treatment and involved a thorough process of random assignment to ensure fairness, as both drugs are administered every three weeks.
Our findings revealed that patients receiving ivonescimab had a significantly longer progression-free survival—the time during which their cancer did not worsen—compared to those on pembrolizumab. Specifically, the median progression-free survival was 11.1 months for ivonescimab versus only 5.8 months for pembrolizumab. Even when looking closely at subgroups of patients, including those with varying levels of PD-L1 expression, ivonescimab consistently showed better outcomes.
While both treatments presented challenges in terms of side effects, ivonescimab was found to have acceptable safety levels. Notably, serious treatment-related adverse events occurred in a smaller percentage of patients on ivonescimab compared to those on pembrolizumab. This suggests that ivonescimab might offer a new, effective first-line treatment option for patients combating this tough form of cancer.
Our findings revealed that patients receiving ivonescimab had a significantly longer progression-free survival—the time during which their cancer did not worsen—compared to those on pembrolizumab. Specifically, the median progression-free survival was 11.1 months for ivonescimab versus only 5.8 months for pembrolizumab. Even when looking closely at subgroups of patients, including those with varying levels of PD-L1 expression, ivonescimab consistently showed better outcomes.
While both treatments presented challenges in terms of side effects, ivonescimab was found to have acceptable safety levels. Notably, serious treatment-related adverse events occurred in a smaller percentage of patients on ivonescimab compared to those on pembrolizumab. This suggests that ivonescimab might offer a new, effective first-line treatment option for patients combating this tough form of cancer.
Read More
8
LKB1 alteration affects immune response
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.
Focus on immune-vulnerability in cancer
We explored how certain genetic changes in lung cancer can hinder the effectiveness of immune treatments. Specifically, we focused on the interactions between the Liver Kinase B1 (LKB1) gene and a group of proteins known as Inhibitor of Apoptosis Proteins (IAPs), along with Janus Kinase 1 (JAK1).
By studying LKB1-mutant lung cancer cells, we discovered that these cells have a heightened dependence on IAPs to resist immune responses. This means that when LKB1 is altered in these cancer cells, they escape the body's immune surveillance system, making treatment more challenging.
However, we also found that when we inhibit the IAPs, it helps to restore a crucial part of the immune response. This leads to the activation of a signaling pathway involving the Stimulator of Interferon Genes (STING), which in turn boosts the infiltration of immune cells that attack tumors.
Using a mouse model that closely mimics human LKB1-mutant lung cancer, we observed enhanced anti-tumor activity when IAPs were blocked. Our findings suggest that targeting the IAP-JAK1 pathway may improve treatment options for patients with LKB1-mutant tumors, particularly by making them more receptive to existing immunotherapies.
By studying LKB1-mutant lung cancer cells, we discovered that these cells have a heightened dependence on IAPs to resist immune responses. This means that when LKB1 is altered in these cancer cells, they escape the body's immune surveillance system, making treatment more challenging.
However, we also found that when we inhibit the IAPs, it helps to restore a crucial part of the immune response. This leads to the activation of a signaling pathway involving the Stimulator of Interferon Genes (STING), which in turn boosts the infiltration of immune cells that attack tumors.
Using a mouse model that closely mimics human LKB1-mutant lung cancer, we observed enhanced anti-tumor activity when IAPs were blocked. Our findings suggest that targeting the IAP-JAK1 pathway may improve treatment options for patients with LKB1-mutant tumors, particularly by making them more receptive to existing immunotherapies.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
8.8
Joint support
I felt the difference! Initially sceptical, I have cancer and arthritis. After just two months on this supplement, I noticed a remarkable change. It is completely flavourless, so I mix it into my coffee every morning and have started gifting it to family and friends suffering from joint pain or brittle nails/hair. Highly recommend!
Read More
